321 results on '"Kellner, Christian"'
Search Results
2. Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
3. Rekrutierung von Natürlichen Killerzellen durch optimierte Immunliganden
4. Engineering an inducible leukemia-associated fusion protein enables large-scale ex vivo production of functional human phagocytes
5. Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
6. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
7. Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade
8. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20
9. Requirements for storing electrophysiology data
10. Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets.
11. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells
12. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
13. Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets
14. An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts
15. Novel NKG2D-directed bispecific antibodies enhance antibodymediated killing of malignant B cells by NK cells and T cells.
16. Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis
17. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
18. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody
19. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
20. Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis
21. Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab
22. Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen
23. Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
24. Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma
25. An Inducible Leukemia-Associated Transcription Factor Facilitates Large-Scale Ex Vivo Generation of Functional Human Macrophages
26. The novel dual topoisomerase inhibitor P8-D6 shows anti-myeloma activity in vitro and in vivo
27. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II–restricted antigen presentation
28. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions
29. Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo
30. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20
31. The selection of variable regions affects effector mechanisms of IgA antibodies against CD20
32. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions
33. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design
34. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein
35. Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody
36. Einfluss des Integrated Reportings auf Urteile und Entscheidungen privater Investoren : theoretische und laborexperimentelle Erkenntnisse
37. Reacting to ambiguous messages: An experimental analysis
38. Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
39. Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia
40. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting
41. Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia
42. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting
43. Optimizing Organ Donation: Expert Opinion from Austria, Germany, Spain and the U.K.
44. Activity-Dependent Calcium Signaling in Neurons of the Medial Superior Olive during Late Postnatal Development
45. Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab
46. Oncogenic deregulation of cell adhesion molecules in leukemia
47. Age-dependent thickening of glomerular basement membrane has no major effect on glomerular hydraulic conductivity
48. Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia
49. Targeting the Glyco-Antigen CD75s with the Tetravalent, Fc-Engineered Antibody 'Ebu-141 Tetra' Induces Potent Killing of B Cell Lymphoma and Plasma Cell Tumors
50. Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.